Business Context and Reporting Period
This Form 6-K filing by Prana Biotechnology Limited (noted as Altery Therapeutics Ltd in metadata) covers the month of May 2004. The registrant is a foreign private issuer based in South Melbourne, Australia. The filing primarily discloses a new issue of securities and an application for quotation on the Australian Securities Exchange (ASX).
Key Financial Metrics and Capital Structure
The filing details a specific capital event rather than providing comprehensive financial statements (revenue, profit, or cash flow are not reported in this document).
- Securities Issued: 200,000 Ordinary Shares.
- Issue Price: $0.70 per share.
- Purpose of Issue: Exercise of options (Code: PBTAS).
- Settlement Date: 8 April 2004.
- Ranking: Pari passu with existing ordinary shares.
- Total Quoted Securities (Post-Issue): 74,159,380 Ordinary Shares.
- Outstanding Options (Unquoted):
- 20,000,000 options exercisable at $0.50 (expiry: 1 Dec 2004).
- 1,347,167 employee/consultant options exercisable at $0.50 (expiry: 30 June 2005).
- 10,000 employee/consultant options exercisable at $1.50 (expiry: 30 June 2005).
- 200,000 options exercisable at $0.70 (expiry: 23 April 2004).
Material Changes
The primary material change is the increase in the number of ordinary shares quoted on the ASX due to the exercise of 200,000 options. The filing confirms that the dividend policy remains unchanged following this capital increase. No other material changes to operations or financial status are disclosed in this specific report.
Guidance, Outlook, and Risks
The filing does not contain management commentary, financial guidance, or an outlook for future periods. It is a procedural disclosure regarding the issuance of shares and the application for their quotation. The registrant warrants that the issue complies with applicable laws and that no illegal purpose is served. The filing notes that ASX quotation is at the absolute discretion of the exchange.
Investor Verification Checklist
- Verify the total number of outstanding options and their respective exercise prices and expiry dates to assess potential future dilution.
- Confirm the current market price of the ordinary shares relative to the $0.70 exercise price of the recently issued shares.
- Review the company's most recent Form 20-F or annual report for revenue, cash flow, and liquidity data, as this Form 6-K does not contain such figures.
- Check the status of the 200,000 options with an expiry date of 23 April 2004 to ensure they were fully exercised or expired as indicated.